CSE:AGN - Post Discussion
Post by
SkywalkerofLuke on Dec 16, 2022 3:33pm
Recent News
With their recent focus on the Phase-1 clinical DMT study it was good to see AGN.c AGNPF was granted FDA Orphan Drug Designation for Ifenprodil (the lead clinical candidate being developed for the treatment of IPF and chronic cough) as a treatment for Idiopathic Pulmonary Fibrosis.
They recently concluded a Phase 2a study of Ifenprodil in patients with IPF which saw patients receiving Ifenprodil experiencing no worsening of their lung function, and significant improvements were seen in the frequency of their IPF-associated cough as well.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/169/algernon-pharmaceuticals-receives-u-s-fda-orphan-drug
Be the first to comment on this post